Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Oslo
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

SER:NO

3.080 NOK 0.0000.00%

As of 10:25:08 ET on 03/02/2015.

Snapshot for Serodus ASA (SER)

Open: - Day's Range: - Volume: 118,233
Previous Close: 3.080 52wk Range: 2.200 - 4.300 1-Yr Rtn: -23.00%

Stock Chart for SER

No chart data available.
  • SER:NO 3.080
  • 1D
  • 1M
  • 1Y
3.080
Interactive SER Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SER

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. OBX -
Earnings Per Share (NOK) (ttm) -0.6580
Est. EPS (NOK) (12/2015) -
Est. PEG Ratio -
Market Cap (M NOK) 84.90
Shares Outstanding (M) 27.56
30 Day Average Volume 20,064
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/24/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SER

  • Revenue
  • Net Income (M/NOK)
  • Profit Margin (%)

Company Profile & Key Executives for SER

Serodus ASA, also known as Serodus Pharmaceuticals, is a Norwegian drug development company. The Company is focused on therapeutic products for the treatment of cardiovascular diseases with large unmet clinical needs. Serodus concentrates on isolated systolic hypertension, chronic congestive heart failure and atrial fibrillation after intra-thoracical surgery.

Hakon SaeteroyChairmanEva SteinessChief Executive Officer
Mogens Vang RasmussenChief Financial OfficerTrygve GulbrandsenChief Operational Officer
More Company Profile & Key Executives for SER

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil